11 results found.

Leukemia, Lymphoma, Unspecified Adult Solid Tumor, Protocol Speci Clinical Trial using allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes

Memorial Sloan-Kettering Cancer Center - Recruiting N/A or older.
- An Evaluation of the Toxicity and Therapeutic Effects of Epstein-Barr Virus-Immune (EBV)-Immune T-Lymphocytes Derived From Normal HLA-Compatible or Haplotype-Matched Donor in the Treatment of EBV-Associated Lymphoproliferative Diseases or Malignancies and Patients With Detectable Circulating Levels of EBV DNA Who Are at High Risk for EBV-Associated Lymphoproliferative Diseases.
allogeneic Epstein-Barr virus-specific cytotoxic T lymphocytes

Chemotherapeutic Agent Toxicity, Cognitive/Functional Effects, Ne Clinical Trial using questionnaire administration; cognitive assessment; psychosocial assessment and care; quality-of-life assessment

Children's Oncology Group - Recruiting 1 Month to 21 years.
- Neuropsychological, Social, Emotional, and Behavioral Outcomes in Children With Cancer.
questionnaire administration; cognitive assessment; psychosocial assessment and care; quality-of-life assessment

Congenital Combined Immunodeficiency, Fungal Infection, Hematopoi Clinical Trial using caspofungin acetate; fluconazole; voriconazole; laboratory biomarker analysis

Children's Oncology Group - Recruiting N/A to 20 years.
- A Phase III Open-Label Trial of Caspofungin vs. Azole Prophylaxis for Patients at High-Risk for Invasive Fungal Infections (IFI) Following Allogeneic Hematopoietic Cell Transplantation (HCT).
caspofungin acetate; fluconazole; voriconazole; laboratory biomarker analysis

Recurrent Melanoma, Recurrent Thyroid Cancer, Thyroid Gland Medul Clinical Trial using cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 2 years to 18 years.
- A Phase 1 Study of XL184 (Cabozantinib, IND# 116059) in Children and Adolescents With Recurrent or Refractory Solid Tumors, Including CNS Tumors.
cabozantinib-s-malate; pharmacological study; laboratory biomarker analysis

Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nau Clinical Trial using Real Acupressure Band; Placebo Acupressure Band

University of South Florida - Recruiting 4 years to 18 years.
- Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy.
Real Acupressure Band; Placebo Acupressure Band

Unspecified Childhood Solid Tumor, Protocol Specific Clinical Trial using tivantinib; pharmacological study; laboratory biomarker analysis

National Cancer Institute (NCI) - Recruiting 13 Months to 21 years.
- A Phase 1 Study of the c-Met Inhibitor, Tivantinib (ARQ 197, IND# 112603) in Children With Relapsed or Refractory Solid Tumors.
tivantinib; pharmacological study; laboratory biomarker analysis

Unspecified Childhood Solid Tumor, Protocol Specific Clinical Trial using carboplatin; cyclophosphamide; etoposide phosphate; gene expression analysis; polymorphism analysis; pharmacological study

National Cancer Institute (NCI) - Recruiting N/A to 2 years.
- Pharmacokinetics and Pharmacogenetics of Anticancer Drugs in Infants and Young Children.
carboplatin; cyclophosphamide; etoposide phosphate; gene expression analysis; polymorphism analysis; pharmacological study

Chemotherapeutic Agent Toxicity, Sarcoma, or Unspecified Childhoo Clinical Trial using gene expression analysis; polymorphism analysis; management of therapy complications

National Cancer Institute (NCI) - Recruiting N/A to 20 years.
- CYP3A5 Genotype as a Potential Risk Factor for the Development of Ifosamide Nephrotoxicity in Children.
gene expression analysis; polymorphism analysis; management of therapy complications

Cancer Survivor, Cardiovascular Complications, Hematopoietic/Lymp Clinical Trial using questionnaire administration; laboratory biomarker analysis

Children's Oncology Group - Recruiting N/A to 21 years.
- Key Adverse Events After Childhood Cancer.
questionnaire administration; laboratory biomarker analysis

Brain and Central Nervous System Tumors, Lymphoma, Neuroblastoma, Clinical Trial using crizotinib; pharmacogenomic studies; pharmacological study

National Cancer Institute (NCI) - Recruiting 1 year to 21 years.
- A Phase I/II Study of PF-02341066, an Oral Small Molecule Inhibitor of Anaplastic Lymphoma Kinase (ALK) and c-Met, in Children With Relapsed/Refractory Solid Tumors, Primary CNS Tumors, and Anaplastic Large Cell Lymphoma.
crizotinib; pharmacogenomic studies; pharmacological study